Ironwood Pharmaceuticals | IRWD - Equity Capital And Reserves


Ironwood Pharmaceuticals reported $-264.16M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
Almirall EUR 1.46B 25.28M Jun/2025
Alnylam Pharmaceuticals USD 233.89M 16.7M Sep/2025
Amarin USD 458.89M 6.03M Sep/2025
Ardelyx USD 154.28M 14.75M Sep/2025
Astellas Pharma JPY 1.76T 150.69B Dec/2025
AstraZeneca USD 45.89B 1.17B Sep/2025
Charles River Laboratories USD 3.41B 52.13M Sep/2025
Exact Sciences USD 2.5B 32M Sep/2025
Halozyme Therapeutics USD 503.92M 171.17M Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Ironwood Pharmaceuticals USD -264.16M 44M Sep/2025
MacroGenics USD 67M 20.38M Sep/2025
Moderna USD 9.33B 69M Sep/2025
Myriad Genetics USD 372.8M 15.3M Sep/2025
Pacira USD 727.21M 30.55M Sep/2025
PTC Therapeutics USD -155.76M 50.79M Sep/2025
Sarepta Therapeutics USD 1.32B 37.26M Sep/2025
Takeda JPY 7.64T 513.39B Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025